ZA200301637B - Peptides presented by cells. - Google Patents

Peptides presented by cells. Download PDF

Info

Publication number
ZA200301637B
ZA200301637B ZA200301637A ZA200301637A ZA200301637B ZA 200301637 B ZA200301637 B ZA 200301637B ZA 200301637 A ZA200301637 A ZA 200301637A ZA 200301637 A ZA200301637 A ZA 200301637A ZA 200301637 B ZA200301637 B ZA 200301637B
Authority
ZA
South Africa
Prior art keywords
peptides
cells
protein
polypeptide
mhc
Prior art date
Application number
ZA200301637A
Other languages
English (en)
Inventor
Francis J Carr
Koen Hellendoorn
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200301637B publication Critical patent/ZA200301637B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200301637A 2000-08-03 2003-02-27 Peptides presented by cells. ZA200301637B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells

Publications (1)

Publication Number Publication Date
ZA200301637B true ZA200301637B (en) 2004-02-03

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301637A ZA200301637B (en) 2000-08-03 2003-02-27 Peptides presented by cells.

Country Status (20)

Country Link
US (1) US20030171290A1 (de)
EP (1) EP1305343B1 (de)
JP (1) JP2004506202A (de)
KR (1) KR20030037272A (de)
CN (1) CN1511164A (de)
AT (1) ATE306498T1 (de)
AU (1) AU2001283958A1 (de)
BR (1) BR0112925A (de)
CA (1) CA2417767A1 (de)
CZ (1) CZ2003464A3 (de)
DE (1) DE60114018T2 (de)
GB (1) GB0018901D0 (de)
HU (1) HUP0301581A2 (de)
MX (1) MXPA03000901A (de)
NO (1) NO20030495L (de)
PL (1) PL358874A1 (de)
RU (1) RU2003105806A (de)
SK (1) SK1982003A3 (de)
WO (1) WO2002012899A2 (de)
ZA (1) ZA200301637B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292778A1 (en) * 2000-09-18 2002-03-26 Genzyme Corporation Method to identify therapeutic antibody targets associated with a therapeutic response
JP4188229B2 (ja) * 2001-06-19 2008-11-26 サントリー株式会社 細胞内に存在するタンパク質又は当該タンパク質と相互作用する物質を分析する方法
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
EP1982176A1 (de) * 2006-01-30 2008-10-22 Dako Denmark A/S Quantifizierung antigenspezifischer t-zellen in vollblut mit hoher geschwindigkeit mittels durchflusszytometrie
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
AU2010314798B2 (en) 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
RU2725542C2 (ru) * 2013-05-13 2020-07-02 Селлектис Способы конструирования высокоактивных т-клеток для иммунотерапии
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
AU2017335084B2 (en) * 2016-09-30 2023-06-29 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3898666A2 (de) 2018-12-17 2021-10-27 Immudex ApS Panel mit borrelia-mhc-multimeren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
AU4676500A (en) * 1999-04-28 2000-11-10 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
SK1982003A3 (en) 2003-08-05
BR0112925A (pt) 2003-08-26
RU2003105806A (ru) 2004-07-20
NO20030495D0 (no) 2003-01-31
WO2002012899A2 (en) 2002-02-14
CA2417767A1 (en) 2002-02-14
PL358874A1 (en) 2004-08-23
US20030171290A1 (en) 2003-09-11
CZ2003464A3 (cs) 2003-06-18
CN1511164A (zh) 2004-07-07
JP2004506202A (ja) 2004-02-26
DE60114018D1 (de) 2006-02-23
NO20030495L (no) 2003-01-31
GB0018901D0 (en) 2000-09-20
DE60114018T2 (de) 2006-06-29
EP1305343A2 (de) 2003-05-02
HUP0301581A2 (hu) 2003-08-28
ATE306498T1 (de) 2005-10-15
MXPA03000901A (es) 2003-06-24
KR20030037272A (ko) 2003-05-12
AU2001283958A1 (en) 2002-02-18
WO2002012899A3 (en) 2002-11-07
EP1305343B1 (de) 2005-10-12

Similar Documents

Publication Publication Date Title
EP1305343B1 (de) Von zellen präsentierte peptide
Wahlström et al. Identification of HLA-DR–bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis
Arif et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health
Guo et al. Characterization of the human salivary proteome by capillary isoelectric focusing/nanoreversed-phase liquid chromatography coupled with ESI-tandem MS
Patel et al. A comparison of labeling and label-free mass spectrometry-based proteomics approaches
US6391649B1 (en) Method for the comparative quantitative analysis of proteins and other biological material by isotopic labeling and mass spectroscopy
US8568993B2 (en) Detection of glycopeptides and glycoproteins for medical diagnostics
US20210285965A1 (en) Proteomic screening for diseases
Strollo et al. Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes
Newman et al. Addressing MISEV guidance using targeted LC‐MS/MS: A method for the detection and quantification of extracellular vesicle‐enriched and contaminant protein markers from blood
de Jong Contribution of mass spectrometry to contemporary immunology
Halgand et al. Defining intact protein primary structures from saliva: a step toward the human proteome project
EP3333571B1 (de) Verfahren und kit zur gleichzeitigen quantifizierung von spleissvarianten des vaskulären endothelialen wachstumsfaktors (vegf-a)
Schmidt et al. Immunoaffinity targeted mass spectrometry analysis of human plasma samples reveals an imbalance of active and inactive CXCL10 in primary Sjogren’s syndrome disease patients
JP2023512401A (ja) 全細胞グリコプロテオミクス分析のための方法
Klug et al. Characterization of MHC ligands for peptide based tumor vaccination
US6747273B2 (en) Methods of detecting protein arginine methyltransferase, and uses related thereto
Demine et al. Biochemical determination of natural tumor-associated T-cell epitopes
HK1063076A (en) Peptides presented by cells
CN111007161B (zh) 一种预测甲氨蝶呤药效的肽段组合物及其定量检测方法与检测试剂盒
Lester Investigation of cellular responses to specific protein haptenation by low molecular weight chemical sensitisers
Heberling Treatment-Induced Antigen Presentation in Cancer
Parapatics et al. Proteomic analysis of low quantities of cellular material in the range obtainable from scarce patient samples
Purcell et al. 9 Mass Spectrometric Applications in
Purcell et al. 9 Mass Spectrometric Applications in Immunoproteomics